天津昂赛细胞基因工程有限公司是一个从事细胞治疗产品、体内外分离与扩增干细胞、基因工程多肽药物和治疗用单克隆抗体、抗感染性疾病及恶性肿瘤疫苗、细胞分型及诊断用试剂、细胞治疗用人体细胞培养液等为主的产品开发研究和生产的公司。细胞产品国家工程研究中心是2004年国家发展计划委员会批准组建的，要求通过技术引进、合作研究、自主开发等多种形式，采用细胞工程、生化工程，基因工程等技术进行干细胞产品的开发、临床应用及其科研成果工程化研究，建立标准化的干细胞分离、监测和保存配套工艺技术和质量控制体系；干细胞治疗性克隆和组织定向分化研发技术平台；利用干细胞治疗性克隆和组织定向分化研发技术平台将抗体工程技术研究与细胞治疗产品产业形成产业化于一体的体系。
天津昂赛细胞基因工程有限公司是为实施工程中心项目而组建的项目法人公司。本公司成立于2004年，在天津开发区注册。
细胞产品国家工程研究中心/天津昂赛细胞基因工程有限公司欢迎国内外致力于我国干细胞事业，生物产业的有识之士加盟，并欢迎为中心/公司的建设和发展献技献策。
Introduction
Tianjin AmCellGene Engineering Co., Ltd. is a company with a development and production portfolio that includes novel cell therapy products, stem cell isolation and expansion technology, genetically engineered protein and antibody therapeutics, vaccines against infectious and malignant diseases, reagents for cell typing and disease diagnosis, and human cell culture media.
National Engineering Center of Cell Products (NECCP) was ratified by National Developing and Reformation Committee in 2004. NECCP are pursuing the development of cell therapy products and their clinical applications through technology transfer, academic and industrial collaborations as well as in-house research and development programs using the state of art cell and genetic engineering technologies. NECCP seeks to establish standardized protocols for stem cell isolation, quality control and storage. The goal of NECCP is to build a streamlined industrial platform so that the cell and genetic technologies and the products can ultimately be applied in the health care and clinical practice.
Tianjin AmCellGene Engineering Co., Ltd. was founded in 2004 and registered in Tianjin Economic-Technological Development Area (TEDA). The company is the commercial arm of NECCP.
National Engineering Research Center of Cell Products and Tianjin AmCellGene Engineering Co., Ltd. warmly invite scientists, engineers and other experts to join us, and we welcome all forms of collaborations and partnership that will help us to build a national center of excellence and a leading biotech company in China
